Search

everythinglearnresearchcommunity

for

Search:↓

The user is considering starting finasteride for hair loss but is concerned about potential side effects due to their estradiol levels being near the upper limit. They have consulted a doctor who confirmed their levels are okay to start the treatment.

The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.

The conversation discusses the effectiveness of different concentrations and dosages of topical finasteride on scalp and serum DHT levels, comparing it to oral finasteride and noting the side effects seem to be fewer at lower dosages. Participants shared experiences and referenced a chart indicating similar scalp DHT reduction with 0.025% topical finasteride as with 1mg oral finasteride, but with fewer side effects.

The user has been taking 0.5 finasteride for 10 months and wants to repeat blood tests, including estradiol. However, their doctor is reluctant to test estradiol, arguing it's typically low in men, and the user is considering seeking a second opinion.

The DNA Trichotest is considered unreliable for predicting hair loss treatment responses, and topical spironolactone is questioned for its effectiveness and safety in cis males. Finasteride and Dutasteride are recommended as more reliable treatments for androgenic alopecia.

A user shared their positive experience with scalp micropigmentation (SMP) to cover hair thinning and a scar, choosing it over hair transplants due to its non-invasive nature and realistic results. They recommend SMP for those struggling with hair loss, emphasizing the importance of finding a trusted artist.

The conversation discusses the differences in inactive ingredients between Sandoz 5mg Finasteride and Proscar/Propecia, questioning the purpose of certain additives like Docusate sodium. It seeks to determine if these differences affect the effectiveness of the treatment for hair loss.

KX-826 users report increased shedding, with some experiencing more shedding at higher concentrations. Users are discussing where to purchase the product.

Hair loss treatments RU and topical spironolactone were compared. No specific results or conclusions were provided.

The user has low testosterone and DHT levels and is considering taking finasteride for Norwood 2 hair loss with diffuse thinning. They are seeking advice on whether low DHT indicates high sensitivity to DHT in the scalp and opinions on their lab values.

A treatment showed a 20% hair density increase in weeks, with nearly a third of participants experiencing significant results, while questions remain about its long-term efficacy and effectiveness across different scalp areas. There is interest in combining it with finasteride and minoxidil for potentially better outcomes.

The conversation discusses the use of topical minoxidil for hair loss and the potential benefits of taking a Minoxidil Response Test to determine enzyme activity related to its effectiveness. Some users have considered or tried alternatives like oral minoxidil or tretinoin, with mixed experiences regarding side effects and effectiveness.

PP405 is criticized for overhyped claims and cherry-picked data, with doubts about its effectiveness compared to minoxidil and finasteride. Many users express skepticism, emphasizing the need for more comprehensive trial results.

The user has been taking oral Finasteride and topical Essengen 6 Plus for hair loss and is experiencing increased depression. They plan to get bloodwork to check hormone levels and are seeking advice on which tests to include.

PP405 shows potential for hair growth, with 31% of advanced balding men experiencing over 20% increase in hair density in 8 weeks. However, skepticism persists due to selective data presentation and lack of long-term results, with comparisons to treatments like minoxidil and finasteride.

The user started taking 1 mg finasteride daily in September 2024 and began derma stamping twice a week, noticing progress initially but now experiencing increased scalp visibility. They are considering adding oral or topical minoxidil to their routine for further improvement.

A 30-year-old male is experiencing hair loss and is concerned about his receding hairline, seeking advice on his Norwood scale classification. He is apprehensive about using Minoxidil and finasteride as treatments.

Cecred hair drops, containing keratin and biotin, are questioned for their effectiveness compared to proven treatments like minoxidil. Users express skepticism, suggesting deceptive marketing and the possibility of undisclosed use of other treatments like finasteride.

Counterfeit minoxidil can be identified by inconsistencies in bottle fill levels, label details, and smell compared to genuine products. Genuine minoxidil has a specific alcohol-based smell and consistency, while counterfeit versions may smell musky and feel greasy.

0.5mg dutasteride reduces scalp DHT more than 1mg finasteride, leading to better hair regrowth results. Users report significant improvement with dutasteride compared to finasteride.

A user shared their pre-finasteride lab results, including DHT, estradiol, testosterone, SHBG, prolactin, FSH, and LH levels. Another user responded, cautioning against making unsupported claims about side effects and recovery.

Setipiprant and Fevipiprant are questioned for their effectiveness in hair maintenance, with skepticism due to lack of convincing results beyond vellus hair growth. The user is satisfied with Minoxidil and Finasteride but is curious about the potential of DP2 inhibitors.

This user has been taking finasteride for several years and recently added topical minoxidil to their regimen, specifically targeting the area of hair loss. They are wondering if this was a wise course of action.

The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.

The conversation is about whether 0.5 mg of finasteride reduces scalp DHT as effectively as 1 mg. Users suggest that even lower doses like 0.05 mg can significantly reduce scalp DHT.

The conversation is about gathering serum DHT data from individuals taking dutasteride to investigate its efficacy, especially in cases with unexpectedly low DHT reduction. The aim is to explore potential genetic factors affecting drug metabolism.

The user is experiencing low libido and mood swings after starting a low dose of topical finasteride. They are considering further blood tests to investigate low testosterone levels and other hormonal factors.

The conversation questions the lack of feedback on the effectiveness of PGE2 and setipiprant for hair loss, despite their availability. The user is puzzled by the absence of reviews or results, whether positive or negative.

The user has been using a topical treatment combining finasteride, minoxidil, and caffeine for 9 months without noticing any changes and is inquiring about blood tests to check for finasteride resistance. They had their DHT levels checked, which were 54 ng/dl, and are planning to share progress pictures soon.

The conversation discusses the uncertainty of the legitimacy of minoxidil products in the EU market and mentions baricitinib as an approved, but expensive alternative. A method to test for real minoxidil involves mixing it with bleach to see if it turns orange or brown.